888-969-2592
Kalkine 0
countryflagCA

Pacific Biosciences of California

Healthcare US PACB

1.015USD
-0.025(2.40%)

Last update at 2025-05-30T16:58:00Z

Day Range

1.001.04
LowHigh

52 Week Range

0.952.72
LowHigh

Fundamentals

  • Previous Close 1.04
  • Market Cap310.59M
  • Volume3183443
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-239.25101M
  • Revenue TTM152.36M
  • Revenue Per Share TTM0.54
  • Gross Profit TTM 42.09M
  • Diluted EPS TTM-2.74

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -314.24800M -274.87200M 29.40M -84.13400M -102.56200M
Minority interest - - - - -
Net income -296.93000M -181.22300M 29.40M -77.81900M -102.56200M
Selling general administrative 160.85M 124.12M 72.80M 75.49M 63.49M
Selling and marketing expenses - - - - -
Gross profit 49.03M 58.86M 32.57M 34.58M 25.10M
Reconciled depreciation 17.32M 11.59M 9.30M 9.95M 7.21M
Ebit -304.81900M -178.16300M -104.38500M -100.54500M -107.35400M
Ebitda -297.18100M -178.07000M -102.33000M -99.52300M -100.13900M
Depreciation and amortization 7.64M 0.09M 2.06M 1.02M 7.21M
Non operating income net other - 0.09M 2.06M 1.02M 0.85M
Operating income -304.81900M -178.16300M -104.38500M -100.54500M -100.98700M
Other operating expenses 433.12M 308.68M 183.28M 191.44M 179.61M
Interest expense 14.69M 12.53M 0.27M 2.61M 2.42M
Tax provision 0.00000M -93.64900M - - -
Interest income - - - 2.61M 2.42M
Net interest income -14.69000M -12.53000M -0.26700M -2.61100M -2.42300M
Extraordinary items - - - - -
Non recurring - 31.13M - - -
Other items - - - - -
Income tax expense -17.31800M -93.64900M -6.98200M -6.31500M 0.85M
Total revenue 128.30M 130.51M 78.89M 90.89M 78.63M
Total operating expenses 353.85M 237.02M 136.95M 135.12M 126.08M
Cost of revenue 79.27M 71.65M 46.33M 56.31M 53.53M
Total other income expense net -9.42900M -96.70900M 133.79M 16.41M 0.85M
Discontinued operations - - - - -
Net income from continuing ops -314.24800M -181.22300M -102.59700M -102.13400M -102.56200M
Net income applicable to common shares -314.24800M -181.22300M 29.40M -84.13400M -102.56200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1260.45M 1746.01M 1767.09M 2006.97M 413.98M
Intangible assets 389.57M 456.98M 410.25M 410.98M -
Earning assets - - - - -
Other current assets 19.47M 17.04M 10.29M 12.49M 4.87M
Total liab 753.85M 1044.71M 1204.18M 1215.98M 78.49M
Total stockholder equity 506.59M 701.30M 562.90M 790.99M 335.49M
Deferred long term liab - - - - -
Other current liab 35.84M 53.54M 21.87M 28.55M 18.29M
Common stock - 0.27M 0.23M 0.22M 0.19M
Capital stock 0.29M 0.27M 0.23M 0.22M 0.19M
Retained earnings -2148.92600M -1839.07500M -1532.34000M -1218.09200M -1036.86900M
Other liab - - 2.60M 214.97M 10.29M
Good will 317.76M 462.26M 409.97M 409.97M -
Other assets - 0.00000M 13.45M 1.17M 33.49M
Cash 55.37M 180.21M 325.09M 460.73M 318.81M
Cash and equivalents - - - - -
Total current liabilities 66.30M 95.03M 76.92M 83.29M 36.49M
Current deferred revenue 13.86M 16.34M 32.29M 36.03M 10.29M
Net debt 617.06M 753.72M 632.28M 493.02M -276.81500M
Short term debt 20.05M 10.08M 10.73M 7.71M 4.33M
Short long term debt - 0.49M 1.84M - -
Short long term debt total 672.43M 933.93M 957.37M 953.75M 42.00M
Other stockholder equity 2655.10M 2539.89M 2099.78M 2009.94M 1372.08M
Property plant equipment - - 81.34M 79.12M 24.90M
Total current assets 495.68M 742.05M 855.00M 1105.73M 354.75M
Long term investments - - - - -
Net tangible assets - - -257.31500M -29.96600M 335.49M
Short term investments 334.56M 451.50M 447.23M 583.67M 237.20M
Net receivables 27.52M 36.62M 18.79M 24.24M 16.84M
Long term debt 647.49M 892.24M 896.68M 896.07M -
Inventory 58.76M 56.68M 50.38M 24.60M 14.23M
Accounts payable 16.59M 15.06M 12.03M 11.00M 3.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.42M 0.22M -4.76500M -1.08700M 0.09M
Additional paid in capital - - - - -
Common stock total equity - - - 0.22M 0.19M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1218.09200M -1036.86900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.84M -443.71000M 10.53M 1.17M 4.38M
Deferred long term asset charges - - - - -
Non current assets total 764.77M 1003.97M 912.09M 901.24M 59.23M
Capital lease obligations 24.94M 41.20M 49.96M 57.68M 42.00M
Long term debt total - - - 896.07M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 116.08M -352.80700M -218.28300M 64.88M -36.56100M
Change to liabilities -2.70900M 32.10M 4.08M 1.57M -2.50600M
Total cashflows from investing activities 116.08M -678.53100M -219.32200M 62.05M -38.41500M
Net borrowings -1.60800M 895.17M -16.00000M -16.00000M -16.00000M
Total cash from financing activities 9.62M 1169.58M 251.84M 26.55M 107.18M
Change to operating activities -22.81200M 8.50M 4.28M -4.09500M -0.59000M
Net income -314.24800M -181.22300M 29.40M -84.13400M -102.56200M
Change in cash -137.50600M 379.87M 52.02M 10.28M 2.34M
Begin period cash flow 465.82M 85.95M 33.93M 23.34M 21.01M
End period cash flow 328.31M 465.82M 85.95M 33.63M 23.34M
Total cash from operating activities -263.21100M -111.18000M 19.50M -78.31200M -66.43000M
Issuance of capital stock 0.00000M 294.85M 187.48M 0.00000M 97.53M
Depreciation 17.32M 11.59M 9.30M 9.95M 7.21M
Other cashflows from investing activities - -319.79300M - 64.88M -36.56100M
Dividends paid - - - - -
Change to inventory -33.90600M -12.43100M -1.09600M 3.92M 3.62M
Change to account receivables 5.46M -7.16600M -1.60300M -6.67100M 4.84M
Sale purchase of stock - 326.65M 233.84M 8.55M 107.18M
Other cashflows from financing activities 116.08M 875.10M 80.36M 18.00M 9.65M
Change to netincome 87.05M 36.91M -16.46700M -1.42100M 22.99M
Capital expenditures 16.93M 5.93M 1.04M 2.84M 1.85M
Change receivables - -7.16600M -1.60300M -6.67100M 4.84M
Cash flows other operating - 24.11M -1.26000M 0.87M -0.29000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 379.87M 52.02M 10.28M 2.34M
Change in working capital -53.97200M 21.00M -2.75900M -3.00400M 5.67M
Stock based compensation 78.61M 73.36M 17.53M 16.40M 23.15M
Other non cash items 9.08M 57.75M -33.87100M -16.78800M 1.02M
Free cash flow -280.14000M -117.11100M 18.46M -81.14800M -68.28400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PACB
Pacific Biosciences of California		 -0.025 2.40% 1.01 - - 2.04 3.39 4.38 -4.1543
ABT
Abbott Laboratories		 -0.055 0.04% 132.79 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -2.02 0.53% 380.33 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.12 0.15% 82.53 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.2 0.19% 104.30 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Pacific Biosciences of California

1305 O?Brien Drive, Menlo Park, CA, United States, 94025

Key Executives

Name Title Year Born
Mr. Christian O. Henry M.B.A. Pres, CEO & Director 1968
Ms. Susan G. Kim Chief Financial Officer 1976
Mr. Mark Van Oene Chief Operating Officer 1973
Dr. Denis Zaccarin Ph.D. Sr. VP of Product Devel. 1966
Dr. Stephen Turner Co-Founder & CTO 1968
Ms. Michele Farmer CPA VP & Chief Accounting Officer 1980
Dr. Jonas Korlach Ph.D. Chief Scientific Officer NA
Trevin Rard Head of Investor Relations NA
Dr. Brett Atkins J.D., Ph.D. Gen. Counsel & Corp. Sec. NA
Ms. Natalie Welch Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.